131 related articles for article (PubMed ID: 33141168)
1. An miRNA signature associated with tumor mutation burden in endometrial cancer.
Zhou H; Chen L; Qin M; Lei Y; Li T; Li H; Cheng X
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33141168
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a novel DNA damage repair-related long non-coding RNA signature in predicting prognosis, immunity, and drug sensitivity in uterine corpus endometrial carcinoma.
Wang T; Ji M; Liu W; Sun J
Comput Struct Biotechnol J; 2023; 21():4944-4959. PubMed ID: 37876625
[TBL] [Abstract][Full Text] [Related]
3. Establishment of the Prognosis Predicting Signature for Endometrial Cancer Patient.
Tang J; Ma W; Luo L
Med Sci Monit; 2019 Nov; 25():8248-8259. PubMed ID: 31678981
[TBL] [Abstract][Full Text] [Related]
4. The combined signatures of G protein-coupled receptor family and immune landscape provide a prognostic and therapeutic biomarker in endometrial carcinoma.
Chen S; Luo X; Yang B; Zhuang J; Guo J; Zhu Y; Mo J
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14701-14719. PubMed ID: 37584707
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of a NAD+ metabolism-derived gene signature to predict the prognosis and immune landscape in endometrial cancer.
Hu D; Du J; Cheng Y; Xing Y; He R; Liang X; Li H; Yang Y
Biomol Biomed; 2024 Mar; 24(2):346-359. PubMed ID: 37688492
[TBL] [Abstract][Full Text] [Related]
6. Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer.
Zhang J; An L; Zhou X; Shi R; Wang H
Ann Transl Med; 2021 Apr; 9(7):551. PubMed ID: 33987249
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of an interpretable radiomic signature for preoperative estimation of tumor mutational burden in lung adenocarcinoma.
Zhang Y; Yang Y; Ma Y; Liu Y; Ye Z
Front Genet; 2024; 15():1367434. PubMed ID: 38660677
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
Makker V; Taylor MH; Aghajanian C; Cohn AL; Brose MS; Simone CD; Cao ZA; Suttner L; Loboda A; Cristescu R; Jelinic P; Orlowski R; Dutta L; Matsui J; Dutcus CE; Minoshima Y; Messing MJ
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38242717
[TBL] [Abstract][Full Text] [Related]
9. Genome Instability-Related miRNAs Predict Survival, Immune Landscape, and Immunotherapy Responses in Gastric Cancer.
Liu Y; Cheng L; Huang W; Cheng X; Peng W; Shi D
J Immunol Res; 2021; 2021():2048833. PubMed ID: 34761007
[TBL] [Abstract][Full Text] [Related]
10. Tumor Mutation Burden as a Cornerstone in Precision Oncology Landscapes: Effect of Panel Size and Uncertainty in Cutoffs.
Budak B; Arga KY
OMICS; 2024 Apr; 28(4):193-203. PubMed ID: 38657109
[TBL] [Abstract][Full Text] [Related]
11. STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity.
Tan J; Egelston CA; Guo W; Stark JM; Lee PP
EBioMedicine; 2024 Mar; 101():105035. PubMed ID: 38401418
[TBL] [Abstract][Full Text] [Related]
12. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges.
Fancello L; Gandini S; Pelicci PG; Mazzarella L
J Immunother Cancer; 2019 Jul; 7(1):183. PubMed ID: 31307554
[TBL] [Abstract][Full Text] [Related]
13.
Li L; Yue P; Zhu J; Li L; Wang K; Yuan G; Song Y
Cancer Invest; 2024 Apr; ():1-12. PubMed ID: 38666471
[TBL] [Abstract][Full Text] [Related]
14. Uncovering a novel DNA repair-related radiosensitivity model for evaluation of radiotherapy susceptibility in uterine corpus endometrial cancer.
Yang H; Qiu Y; Chen J; Lai J
Heliyon; 2024 Apr; 10(8):e29401. PubMed ID: 38628740
[TBL] [Abstract][Full Text] [Related]
15. Restriction site associated DNA sequencing for tumour mutation burden estimation and mutation signature analysis.
McGuinness CF; Black MA; Dunbier AK
Cancer Med; 2023 Dec; 12(23):21545-21560. PubMed ID: 37974533
[TBL] [Abstract][Full Text] [Related]
16. Predicting gastric cancer tumor mutational burden from histopathological images using multimodal deep learning.
Li J; Liu H; Liu W; Zong P; Huang K; Li Z; Li H; Xiong T; Tian G; Li C; Yang J
Brief Funct Genomics; 2024 May; 23(3):228-238. PubMed ID: 37525540
[TBL] [Abstract][Full Text] [Related]
17. Are we ready to use TMB in breast cancer clinical practice?
Ravaioli S; Limarzi F; Tumedei MM; Palleschi M; Maltoni R; Bravaccini S
Cancer Immunol Immunother; 2020 Oct; 69(10):1943-1945. PubMed ID: 32725361
[TBL] [Abstract][Full Text] [Related]
18. Clinical availability and characteristics of multigene panel testing for recurrent/advanced gynecologic cancer.
Kitazawa S; Chiyoda T; Nakamura K; Sakai K; Yoshihama T; Nishio H; Kobayashi Y; Iwata T; Banno K; Yamagami W; Nishihara H; Aoki D
Int J Clin Oncol; 2023 Nov; 28(11):1554-1562. PubMed ID: 37574505
[TBL] [Abstract][Full Text] [Related]
19. Understanding the Impact of Population and Cancer Type on Tumor Mutation Burden Scores: A Comprehensive Whole-Exome Study in Cancer Patients From India.
Tanwar NA; Malhotra R; Satheesh AP; Khuntia SP; Sreekanthreddy P; Varghese L; Kolla S; Chandrani P; Choughule A; Pange P; Gupta V; Noronha V; Patil VM; Pramanik R; Kumar S; Nayak SP; Babu S; Shetty R; Kantharaju M; Chinder PS; Korlimarla A; Srinath BS; Prabhash K; Rishi KD; Goswami HM; Veldore VH
JCO Glob Oncol; 2023 Sep; 9():e2300047. PubMed ID: 38085046
[TBL] [Abstract][Full Text] [Related]
20. miREC: a database of miRNAs involved in the development of endometrial cancer.
Ulfenborg B; Jurcevic S; Lindlöf A; Klinga-Levan K; Olsson B
BMC Res Notes; 2015 Mar; 8():104. PubMed ID: 25889518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
